The New American Urological Association Benign Prostatic Hyperplasia Clinical Guidelines: 2019 Update

Dornbier, Ryan; Pahouja, Gaurav; Branch, Jeffrey; McVary, Kevin T.

doi:10.1007/s11934-020-00985-0

Cited by 31 publications

(25 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The success of the procedure is determined by patient-reported symptom relief on 3-month follow-up appointment and not the degree of prostate volume loss. The AUA considers PAE investigational as of an update in 2020 [4,53].…”

Section: Prostate Artery Embolization (Pae)mentioning

confidence: 99%

MRI Evaluation of Patients Before and After Interventions for Benign Prostatic Hyperplasia: An Update

Diaz

Benson

Clinkenbeard

et al. 2022

American Journal of Roentgenology

View full text Add to dashboard Cite

The publication of this Accepted Manuscript is provided to give early visibility to the contents of the article, which will undergo additional copyediting, typesetting, and review before it is published in its final form. During the production process, errors may be discovered that could affect the content of the Accepted Manuscript. All legal disclaimers that apply to the journal pertain. The reader is cautioned to consult the definitive version of record before relying on the contents of this document.

show abstract

Section: Prostate Artery Embolization (Pae)mentioning

confidence: 99%

MRI Evaluation of Patients Before and After Interventions for Benign Prostatic Hyperplasia: An Update

Diaz

Benson

Clinkenbeard

et al. 2022

American Journal of Roentgenology

View full text Add to dashboard Cite

show abstract

“…IPSS was assessed at the first and second visits. IPSS includes questions regarding incomplete emptying, frequency intermittency, urgency, weak stream, straining, and nocturia [1]. At the end of the study, all the parameters and scores were compared from baseline to end of study.…”

Section: Exclusion Criteriamentioning

confidence: 99%

“…Benign prostatic hyperplasia (BPH) is the most common benign tumor in men and is responsible for urinary symptoms in majority of males over the age of 50 years [1]. It refers to the proliferation of smooth muscles and epithelial cells within the prostatic transition zone [2].…”

Section: Introductionmentioning

confidence: 99%

Assessment of Comparative Patient Satisfaction and Side-Effects Associated With Tamsulosin Versus Silodosin Therapy in Benign Prostate Hyperplasia

Jayakumar

Varghese

Johnson

et al. 2021

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: The aim of our study was to assess the comparative patient satisfaction and side-effects of the currently prescribed drugs – tamsulosin and silodosin for benign prostatic hyperplasia (BPH). Methods: A prospective study was conducted in a total of 110 BPH patients from the Department of Urology for a period of 6 months. Fifty-five patients in each group received silodosin 8 mg or tamsulosin 0.4 mg once daily. Data were collected using a suitably designed pro forma and the patient satisfaction was assessed with patient’s perception of study medication (PPSM) scale. International prostate symptom score (IPSS) was used for assessing the severity of symptoms. Results: The current study found that the treatment had a significant effect on improving scores of PPSM and IPSS at which all changes were significant at p<0.01 (paired t-test). An independent t-test showed that silodosin group had a greater improvement in PPSM scores – PPSM total by 40.4%, PPSM global by 43.7%, and PPSM pain by 0.39% which was supported by corresponding decline in IPSS scores. The side effects reported for tamsulosin were headache (5.5%), dizziness (5.5%), dry mouth (3.6%), and postural hypotension (14.4%) and those reported for silodosin were myalgia (5.5%), dizziness (7.3%), diarrhea (1.8%), and postural hypotension (10.9%). Conclusion: Patient satisfaction was improved by both the alpha blockers but silodosin showed a significantly greater increase in patient satisfaction than tamsulosin. Thus, silodosin is the better drug of choice.

show abstract

“…Almost 50% of men have at least moderate lower urinary tract symptoms in the eighth decade of life [2]. Transurethral resection of the prostate (TURP) and open simple prostatectomy were historically the standard treatments to remove prostatic obstruction [3]. These procedures require however hospitalization and carry a risk of bleeding, sexual dysfunction, urinary incontinence, and urethral stricture/bladder neck contracture [4,5].…”

Section: Introductionmentioning

confidence: 99%

“…These procedures require however hospitalization and carry a risk of bleeding, sexual dysfunction, urinary incontinence, and urethral stricture/bladder neck contracture [4,5]. Over the last 30 years, a multitude of treatments for BPH, including drugs (α-adrenergic antagonists, 5-α reductase inhibitors) and minimally invasive surgical techniques with the potential to reduce the need for hospitalization and complications [3,6], were introduced into clinical practice [7]. Guidelines recommend conservative measures, including behavioral changes and drugs, as the first-line treatment for men with BPH who are bothered by their LUTS [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

High regional variation in prostate surgery for benign prostatic hyperplasia in Switzerland

et al. 2021

View full text Add to dashboard Cite

Background Among various treatment options for benign prostatic hyperplasia (BPH), surgical therapy is the most invasive. As Switzerland has the highest transurethral prostatectomy rate among OECD countries, we assessed the regional variation in prostate surgery for BPH and explored potential determinants of variation. Methods We conducted a population-based analysis using discharge data for men aged ≥40 years with transurethral or simple prostatectomy from all Swiss hospitals during 2013–2018. After excluding patients with genitourinary/prostate cancer, we derived hospital service areas (HSAs) by analyzing patient flows. We calculated age-standardized mean procedure rates and variation indices (extremal quotient [EQ] and systematic component of variation [SCV]). We estimated the reduction in variance across HSAs of prostatectomy rates in multilevel regression models, with incremental adjustment for age, regional cultural and socioeconomic factors, disease burden, density of urologists, and the time since urologists’ graduation. Results Overall, 44,253 prostatectomies (42,710 transurethral and 1543 simple) from 44 HSAs were analyzed. The mean age-standardized prostate surgery rate was 314 (range 166–500) per 100,000 men aged ≥40 years per year. The EQ was 3.01 and the SCV 5.53, indicating a high regional variation. In multivariate models, men aged 75–79 years had an 11.6-fold higher prostatectomy rate than those aged 50–54 years. French/Italian language areas had a 21% lower rate than Swiss German speaking areas. Socioeconomic factors, disease burden, and density of urologist/time since graduation were not associated with prostatectomy rates. After full adjustment, 80% of the variance in prostate surgery across HSAs remained unexplained. Conclusion We found a remarkably high regional variation in prostate surgery rates for BPH within Switzerland.

show abstract

The New American Urological Association Benign Prostatic Hyperplasia Clinical Guidelines: 2019 Update

Cited by 31 publications

References 97 publications

MRI Evaluation of Patients Before and After Interventions for Benign Prostatic Hyperplasia: An Update

MRI Evaluation of Patients Before and After Interventions for Benign Prostatic Hyperplasia: An Update

Assessment of Comparative Patient Satisfaction and Side-Effects Associated With Tamsulosin Versus Silodosin Therapy in Benign Prostate Hyperplasia

High regional variation in prostate surgery for benign prostatic hyperplasia in Switzerland

Contact Info

Product

Resources

About